Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991279 | 1.00 | MAPT (0.54) | MAPTSMN1; SMN2HDAC3HDAC1HDAC2 | |
| SCHEMBL13801959 | 0.88 | CYP3A4 (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL31139332 | 0.88 | PDK1 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL8711740 | 0.88 | AURKA (0.50) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1858721 | 0.88 | PDK1 (0.58) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL1865895 | 0.87 | AURKA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL7911540 | 0.87 | AURKA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL16246277 | 0.87 | AURKA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL30632213 | 0.87 | AURKA (0.49) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL29969056 | 0.87 | AURKA (0.52) | HDAC3HDAC1HDAC2HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PROMEGA CORPORATION | 2024-02-29 | — | — | US | disclosed |
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | PROMEGA CORPORATION (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | TXINNO BIOSCIENCE INC. (KR) | 2023-05-25 | — | — | US | disclosed |
| WO-2021225407-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE INHIBITORY ACTIVITY, AND USE THEREOF | 주식회사 티씨노바이오사이언스 (KR) | 2021-11-11 | — | — | WO | disclosed |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | PROMEGA CORPORATION (US) | 2020-06-02 | — | — | US | disclosed |
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2020-04-16 | — | — | US | disclosed |
| WO-2019174601-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITOR | FUJIAN HAIXI PHARMACEUTICALS CO., LTD (CN) | 2019-09-19 | — | — | WO | disclosed |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | PROMEGA CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) | 2019-05-21 | — | — | US | disclosed |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2017-08-17 | — | — | US | disclosed |
| CN-104311486-A | 2-oxo-1,2-dihydro-quinoline modulators of immune function | TEVA PHARMA | 2015-01-28 | — | — | CN | disclosed |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | ABBVIE INC. | 2012-07-19 | — | — | US | disclosed |
| US-8114893-B2 | Compounds and methods of use | GENENTECH, INC. (US) | 2012-02-14 | — | — | US | disclosed |
| CN-102143949-A | 2-carbonyl-1, 2-dihydroquinoline modulators of immune function | TEVA PHARMA | 2011-08-03 | — | — | CN | disclosed |
| EP-2337779-A2 | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | Teva Pharmaceutical Industries Ltd. (IL) | 2011-06-29 | — | — | EP | disclosed |
| US-7935699-B2 | Pyrazole glucokinase activators | HOFFMANN-LA ROCHE INC. (US) | 2011-05-03 | — | — | US | disclosed |
| WO-2010028015-A2 | 2-OXO-1,2-DIHYDRO-QUINOLINE MODULATORS OF IMMUNE FUNCTION | AUSPEX PHARMACEUTICALS, INC (US) | 2010-03-11 | — | — | WO | disclosed |
| US-20080021032-A1 | Pyrazole glucokinase activators | BERTHEL STEVEN JOSEPH | 2008-01-24 | — | — | US | disclosed |
| WO-2007044449-A2 | NOVEL PYRAZOLOPYRIMIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS | SCHERING CORPORATION (US) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11781168-B2 | Process for preparing substituted imidazo[1,2-α]pyrazines | CYP4Z1, CYP2E1, CYP2F1 | MAPT 2877/4885SMN1; SMN2 2626/4885HDAC3 1408/4885 |
| US-20200115356-A1 | Modulation of Bacterial Quorum Sensing With Synthetic Ligands | AHCYL1, EBPL, AIP | MAPT 4822/4885SMN1; SMN2 4883/4885HDAC3 2709/4885 |
| US-10294237-B2 | Bicyclic heterocyclic amide derivative | NR0B1, NR2E1, NR0B2 | MAPT 4815/4885SMN1; SMN2 3595/4885HDAC3 71/4885 |
| US-20190241932-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAPT 4859/4885SMN1; SMN2 3970/4885HDAC3 446/4885 |
| US-20170233789-A1 | COELENTERAZINE ANALOGUES | GLB1, SI, TCF7L2 | MAPT 4859/4885SMN1; SMN2 3970/4885HDAC3 446/4885 |
| US-20240068009-A1 | SUBSTITUTED IMIDAZO[1,2-a]PYRAZINES AS LUCIFERASE SUBSTRATES | PGLS, AADAC, GLB1 | MAPT 4849/4885SMN1; SMN2 4438/4885HDAC3 922/4885 |
| US-20230159469-A1 | NOVEL PHTHALAZINE DERIVATIVE HAVING ECTONUCLOEOTIDE PYROPHOSPHATASE/PHOSPHODIESTE RASE INHIBITORY ACTIVITY, AND USE THEREOF | ENPP1, ENPP3, PPA1 | MAPT 2828/4885SMN1; SMN2 3741/4885HDAC3 1770/4885 |
| US-20120184541-A1 | COMPOUNDS AND METHODS OF USE | BCL2A1, BCL2, BAX | MAPT 4858/4885SMN1; SMN2 1830/4885HDAC3 3283/4885 |
| US-20080021032-A1 | Pyrazole glucokinase activators | GCKR, GCK, GALK1 | MAPT 3888/4885SMN1; SMN2 4412/4885HDAC3 958/4885 |
| US-10669568-B2 | Substituted imidazo[1,2-a]pyrazines as luciferase substrates | AADAC, PGLS, GLB1 | MAPT 4847/4885SMN1; SMN2 4453/4885HDAC3 880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.